HDAC9 and breast cancer: Similar strategies for targeting a signaling pathway from multiple directions have proven effective in other cancers, as one study highlights that mTORC and HDAC inhibition mechanistically converged on the PI3K/AKT/mTOR pathway to reduce breast cancer cell viability [48].